Understanding why some hemophilia patients of Mexican descent develop antibodies to factor VIII
Official title: Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent
Funded at University of Texas Rio Grande Valley · NIH-11387778 · Data updated 2026-11-12
Researchers are studying why people with severe hemophilia A who are of Mexican descent are more likely to develop inhibitors to standard factor VIII therapy, using genetic and environmental clues from a large patient group.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $658,485 |
| NIH project number | 5R01HL169763-03 |
| Project ID | NIH-11387778 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with severe hemophilia A seeking FVIII therapy, particularly those of Mexican descent or ancestry.
✕Less likely to help
Patients without Mexican ancestry or those not at risk for inhibitor development may see limited direct benefit from this study.
What this research studies
This project will enroll 200 severe hemophilia A patients of Mexican ancestry and combine new and existing data from about 400 similar subjects. It will use whole-genome sequencing, mRNA sequencing, and CD4 T-cell data, along with detailed clinical information and FVIII antigen status, to identify factors linked to inhibitor development. The study brings together US and Mexico sites and leverages the My Life, Our Future repository to build a 600-person cohort for robust analysis. The goal is to map genetic and environmental contributors to the higher FEI risk in this population and to better understand the immune response to FVIII therapy. Results could guide personalized risk assessment and future therapies to reduce inhibitor formation.
Why it matters
Potential benefit: Better understanding of who is at risk for FVIII inhibitors could lead to more personalized treatment plans and improved outcomes for patients with hemophilia A.
How similar studies have gone: Previous studies have shown that genetic and immune factors influence inhibitor risk, with stronger signals expected in this well-characterized cohort.
Where this research is happening
-
University of Texas Rio Grande Valley
Edinburg, United States Active
Researchers
- Principal investigator: Howard, Tom Eugene — University of Texas Rio Grande Valley
- Study coordinator: Howard, Tom Eugene
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.